GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
| Title: | GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial |
|---|---|
| Authors: | Capone S; Fusco FM; Milleri S; Borrè S; Carbonara S; Lo Caputo S; Leone S; Gori G; Maggi P; Cascio A; Lichtner M; Cauda R; Dal Zoppo S; Cossu MV; Gori A; Roda S; Confalonieri Paola; Bonora S; Missale G; Codeluppi M; Mezzaroma I; Capici S; Pontali E; Libanore M; Diani A; Lanini S; Battella S; Contino AM; Piano Mortari E; Genova F; Parente G; Dragonetti R; Colloca S; Visani L; Iannacone C; Carsetti R; Folgori A; Camerini R; Confalonieri Marco; COVITAR study group |
| Contributors: | Capone, S; Fusco, Fm; Milleri, S; Borrè, S; Carbonara, S; Lo Caputo, S; Leone, S; Gori, G; Maggi, P; Cascio, A; Lichtner, M; Cauda, R; Dal Zoppo, S; Cossu, Mv; Gori, A; Roda, S; Confalonieri, Paola; Bonora, S; Missale, G; Codeluppi, M; Mezzaroma, I; Capici, S; Pontali, E; Libanore, M; Diani, A; Lanini, S; Battella, S; Contino, Am; Piano Mortari, E; Genova, F; Parente, G; Dragonetti, R; Colloca, S; Visani, L; Iannacone, C; Carsetti, R; Folgori, A; Camerini, R; Confalonieri, Marco; COVITAR study, Group |
| Publication Year: | 2023 |
| Collection: | Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) |
| Subject Terms: | CD4; CD8; COVID-19; Sars-CoV-2 vaccine; T cell response; immunological memory; neutralizing antibodie; phase 2 clinical trial; safety; simian adenoviral vector |
| Description: | The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed. |
| Document Type: | article in journal/newspaper |
| File Description: | ELETTRONICO |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/37315558; info:eu-repo/semantics/altIdentifier/wos/WOS:001038001600001; volume:4; issue:6; firstpage:"-"; lastpage:"-"; numberofpages:23; journal:CELL REPORTS MEDICINE; https://hdl.handle.net/11368/3049898; https://www.sciencedirect.com/science/article/pii/S2666379123002033?via=ihub; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243192/ |
| DOI: | 10.1016/j.xcrm.2023.101084 |
| Availability: | https://hdl.handle.net/11368/3049898; https://doi.org/10.1016/j.xcrm.2023.101084; https://www.sciencedirect.com/science/article/pii/S2666379123002033?via=ihub; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243192/ |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.26DADB03 |
| Database: | BASE |